Cicel Science & Technology has entered into an agreement to distribute Mazor Robotics' Renaissance system in China.
Renaissance system is a next generation surgical guidance system used for spine procedures.
As part of the agreement, Cicel will also buy three Renaissance systems to pursue regulatory clearance from the State Food and Drug Administration (SFDA) in China.
Following the receipt of SFDA approval, Cicel will gain three years of exclusive rights to commercialize and distribute the Renaissance system in China.
Mazor Robotics CEO Ori Hadomi said Cicel has established relationships with the hospitals and medical organizations in China, and in addition to the company’s extensive sales and marketing capability it has a full clinical organization with a track record for securing regulatory clearance.
"We are extremely excited to establish our foothold in this key global market with Cicel as our partner," Hadomi added.